Abstract

Breast cancer is a major problem in the health sector worldwide. The prevalence of breast cancer incidence is on the rise in many countries despite efforts to eradicate it. The substantial efforts for the treatment of breast cancer are quite successful but the main hindrance is early detection which in turn is dependent on various factors i.e. genetic history, environmental exposures, hormonal causes, and sedentary lifestyle. In previous studies, lncRNAs were known to modulate the progression of many cancers like gastric, lung, ovarian, and colorectal cancers. This study was designed to find these lncRNAs role in breast cancer development. Bioinformatics tools were used for in silco analysis of these lncRNAs LINC01356, LINC01357, ARF4-AS1, and FAM83B. These lncRNAs were evaluated in GEPIA2 for subtype analysis and survival probability, Phylo CSF UCSC genome browser for conserved sequences and protein-coding potential, BcGenExMiner for correlation analysis and UALCAN for protein-coding gene expression. These above-mentioned lncRNAs showed high expression in the basal subtype of TNBC as compared with other subtypes and they showed poor survival rates in the basal subtype. LINC01356 and LINC01357 showed positive correlation with TAFA3 and SLC16A1. ARF4-AS1 positively correlated with ASB14 and FAM83B positively correlated with HCRTR2. These lncRNAs showing positive correlation with different genes have a role in breast cancer development and progression.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.